Katie Bullinger
Epilepsy · Atlanta, GANPI 1295026664
Payments from drug & device makers
What this record shows
Medtronic accounts for 69.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $2,419 and has fallen 78.4% since, to $523 in 2025.
Across 30 payments — averaging $117.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Neuropace, Inc.$676
- UCB, Inc.$209
- SK Life Science, Inc.$128
- AbbVie$29
- Eisai Inc.$19
Across 236 payments — averaging $463.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neuropace, Inc.$100K
- UCB SA$9K
What the payments were for
- Travel & lodging$1,82852%
- Food & beverage$1,68948%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $2,457 |
| Neuropace, Inc. | 6 | $676 |
| UCB, Inc. | 3 | $209 |
| SK Life Science, Inc. | 2 | $128 |
| AbbVie | 1 | $29 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$1,926
- RNS Neurostimulator Kit$596
How this compares
Too few epilepsy providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 67 | $5,258 |
| Lacosamide | 61 | $3,748 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $1,755 |
| Oxcarbazepine | 21 | $1,752 |
| Zonisamide | 17 | $882 |
| Lamotrigine | 22 | $635 |
| Topiramate | 17 | $325 |
| Clonazepam | 15 | $309 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Atlanta
- Ezequiel GleichgerrchtAtlanta$10K
- Rebecca MatthewsAtlanta$7K
- Ekta ShahAtlanta$3K
- Aida RismanAtlanta$2K
- Daniel WinkelAtlanta$706
- Brian CabanissAtlanta$241
- Charles EpsteinAtlanta$158
- Danielle WeissAugusta$5K
- Kohilavani VelayudamDuluth$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.